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Abstract
Background: We have previously reported that cyclin-dependent kinase 5 (Cdk5) participates in the regulation of
nociceptive signaling. Through activation of the ERK1/2 pathway, Tumor Necrosis Factor-a (TNF-a) induces
expression of Egr-1. This results in the sustained and robust expression of p35, a coactivator of Cdk5, in PC12 cells,
thereby increasing Cdk5 kinase activity. The aim of our present study was to test whether resveratrol, a
polyphenolic compound with known analgesic activity, can regulate Cdk5/p35 activity.
Results: Here we used a cell-based assay in which a p35 promoter-luciferase construct was stably transfected in
PC12 cells. Our studies demonstrate that resveratrol inhibits p35 promoter activity and also blocks the TNF-a
mediated increase in Cdk5 activity in PC12 cells. Resveratrol also inhibits p35 expression and blocks the TNF-a
mediated increase in Cdk5 activity in DRG neurons. In the presence of resveratrol, the MEK inhibitor decreased p35
promoter activity, whereas the inhibitors of p38 MAPK, JNK and NF-B increased p35 promoter activity, indicating
that these pathways regulate p35 expression differently. The TNF-a-mediated increase in Egr-1 expression was
decreased by resveratrol treatment with a concomitant reduction in p35 expression and protein levels, resulting in
reduced Cdk5 kinase activity.
Conclusions: We demonstrate here that resveratrol regulates p35 promoter activity in PC12 cells and DRG
neurons. Most importantly, resveratrol blocks the TNF-a-mediated increase in p35 promoter activity, thereby
reducing p35 expression and subsequent Cdk5 kinase activity. This new molecular mechanism adds to the known
analgesic effects of resveratrol and confirms the need for identifying new analgesics based on their ability to
inhibit Cdk5 activity for effective treatment of pain.
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Background
Resveratrol, a naturally occurring polyphenol found
mainly in red wine, grapes and berries, has been shown
to have many therapeutic values. It is known to protect
against heart disease and cancers, promote anti-aging
effects, suppress neuronal degeneration and also act as
an analgesic [1-5]. Earlier studies indicated that intra-
peritoneal administration of resveratrol decreases hyper-
algesia in the rat model of inflammatory pain, which
was induced by carrageenan injection in the hind paw
[6], and this was attributed to the previously reported
inhibitory effects of resveratrol on cyclooxygenase
(COX)-2 expression [7]. Intra-cerebral injections of
resveratrol also suppressed hyperalgesia in the rat model
of thermal pain with a concomitant inhibition of COX-1
and COX-2 [8]. Similar analgesic effects of resveratrol
were also observed in the rat model of diabetic neuro-
pathic pain [9,10]. All of these studies indicate that
resveratrol has analgesic properties against acute and
chronic pain that is triggered either by inflammation,
heat or a diabetic condition. Although some of these
studies have linked this analgesic action of resveratrol
with altered expression of TNF-a and nitric oxide in the
diabetic rat model [10] and reduced expression of COX-
2 in the inflammatory pain model [11], there is a lack of
clear understanding as to how resveratrol brings about
its analgesic action.
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pain signaling [12,13]. Cdk5 is a proline-directed serine/
threonine protein kinase that belongs to the family of
cyclin-dependent kinases. It is expressed in all tissues,
but it is functionally active mainly in the neurons where
its activators, p35 and p39, are predominantly expressed.
We and others have previously reported that expression
of Cdk5 and p35, as well as Cdk5 kinase activity, was
increased in the dorsal root ganglia (DRG) and the
spinal cord (SC) after peripheral-inflammation
[12,14,15]. Inflammation induced by carrageenan injec-
tion [14] or by complete Freund’sa d j u v a n t( C F A )[ 1 5 ]
in the hind paws of mice increased the mRNA and pro-
tein levels of Cdk5/p35 in nociceptive neurons with a
subsequent increase in Cdk5 kinase activity. Further-
more, we also identified that the elevated Cdk5 activity
phosphorylates transient receptor potential vanilloid 1
(TRPV1), a key receptor that modulates agonist-induced
calcium influx in the neurons [16]. In addition, Cdk5-
mediated phosphorylation of the δ-opioid receptor
impaired receptor function and attenuated morphine
anti-nociceptive tolerance [17]. Additionally, we found
that inflammation triggers an increase in Cdk5 activity
through activation of early growth response 1 (Egr-1)
and p35 expression by TNF-a [13,18]. These findings
suggest that Cdk5 plays an important role in the mole-
cular mechanisms involved in pain signaling. To charac-
terize a possible link between the analgesic effects of
resveratrol and the role of Cdk5 in pain signaling, we
set out to determine if resveratrol affects Cdk5 activity
and, if it does, to characterize the mechanism by which
it brings about this effect.
Results
Generation of p35 promoter-luciferase stable clones
As reported earlier, we developed a cell-based assay
using a transient transfection of PC12 cells with the p35
promoter-luciferase construct. With this assay we
screened the effects of proinflammatory molecules on
p35 promoter activity and found that TNF-a treatment
of these cells significantly increased p35 promoter activ-
ity [18]. In order to establish a consistent cell-based
assay, we generated several stable clones of the p35 pro-
moter-luciferase in PC12 cells. Briefly, we cloned a
1,219-bp fragment of mouse p35 promoter [19] into the
pGL4.17 (luc2/Neo) vector (Figure 1A). p35 promoter-
luciferase vector was stably transfected into PC12 cells
and subjected to G418 selection for four weeks, yielding
7 stable clones. As described in Materials and Methods,
to test the functionality of these stable clones we ana-
lyzed the effects of TNF-a on their p35 promoter activ-
ity. All stable clones responded to TNF-a treatment (25
ng/ml), which resulted in increased p35-promoter activ-
ity, and based on this testing we selected the stable
clone C7 for further experimentation (data not shown)
and the effects of different concentrations of TNF-a on
p35 promoter activity were further analyzed in the
stable clone C7. TNF-a treatment increased p35 promo-
ter activity in a dose-dependent manner, and at the
Figure 1 Generation of p35 promoter-luciferase stable clones.
A) Schematic representation of the p35 promoter-luciferase vector
(6.8 kb). It consists of a 1,219-bp fragment of a mouse p35
promoter cloned into a pGL4.17 (luc2/Neo) vector. B) TNF-a
treatment at different concentrations increased p35 promoter
activity in a dose-dependent manner at 24 h in stable clone C7
cells. C) At all levels of TNF-a concentrations that were tested, cell
viability as measured by MTS assay was similar to the control. All
data are presented as the mean and SEM (n = 3). * p< 0.05, ** p <
0.01, ***p < 0.0001 (Dunett’s test after ANOVA).
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activity increased by 250% compared to the control (Fig-
ure 1B). At all TNF-a concentrations tested, cell viabi-
lity measured by MTS assay (as described in Materials
and Methods) was similar to the control (Figure 1C).
Resveratrol inhibits p35 promoter luciferase activity
We analyzed the effects of different concentrations of
resveratrol on p35 promoter activity in the stable clone
C7, and we found that resveratrol significantly decreased
p35 promoter activity in a dose-dependent manner (Fig-
ure 2A). Resveratrol treatment decreased p35 promoter
activity at a concentration of 5 μM, which was followed
by a linear decrease with higher concentrations of up to
50 μM. At a concentration of 25 μM, p35 promoter
activity decreased by 70% compared to the control. We
also evaluated the cell viability of stable clones by MTS
assay and found that cell viability remained unchanged
Figure 2 Resveratrol inhibits p35 promoter activity. A) Resveratrol treatment for 24 hr at different concentrations decreased p35 promoter
activity in a dose-dependent manner in stable clone C7 cells. B) Cell viability was unchanged in up to 25 μM of resveratrol, but at 50 μM and
100 μM it was reduced significantly in comparison to the control. C) Resveratrol treatment (10 μM) decreased p35 promoter activity in a time-
dependent manner. D) Stable clone C7 cells were treated with TNF-a (50 ng/ml), resveratrol (25 μM), and TNF-a (50 ng/ml) plus resveratrol (25
μM) during 24 h and p35 promoter activity was measured. Resveratrol blocked the TNF-a mediated increase in p35 expression. All data are
presented as the mean and SEM (n = 4). *p <0.05, ***p < 0.0001 (Bonferroni test after ANOVA).
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100 μM of resveratrol, cell viability was reduced by 16%
and 27% compared to the control, respectively, which
confirms earlier reports [20]. Next, we determined the
time-course of decrease in p35 promoter activity with
the resveratrol treatment. Stable clone C7 cells treated
with resveratrol (10 μM) showed a time-dependent
decrease in the p35 promoter activity (Figure 2C).
Resveratrol treatment significantly decreased the p35
promoter activity, starting as early as 1 h after the treat-
ment and reaching a further decrease at 6 h and 24 h.
Furthermore, we tested whether resveratrol can block
the increase in p35 promoter activity induced by TNF-a
treatment. Stable clone C7 cells were treated with TNF-
a (50 ng/ml) and resveratrol (25 μM) for 24 h, and this
resulted in a significant decrease in p35 promoter activ-
ity (Figure 2D). Together, these results indicate that
resveratrol treatment significantly decreases the p35 pro-
moter activity in PC12 cells in a dose- and time-depen-
dent manner, and also that resveratrol can block a TNF-
a mediated increase in the p35 promoter activity.
Resveratrol treatment significantly decreases p35
expression and Cdk5 activity in PC12 cells and DRG
neuronal culture
To further examine the inhibitory effects of resveratrol
on p35 promoter expression, we examined endogenous
levels of p35 mRNA and protein at different time points
following treatment with resveratrol. The level of p35
mRNA decreased significantly within 6 h after resvera-
trol treatment (25 μM) (Figure 3A), and the p35 protein
level decreased significantly in PC12 cells (Figure 4A
and 4B) and in rat DRG neuronal culture (Figure 4D) at
24 h following resveratrol treatment (25 μM). Moreover,
we tested if resveratrol can block the increase in p35
mRNA induced by TNF-a. When PC12 cells were trea-
ted with TNF-a (50 ng/ml) and resveratrol (25 μM) for
3 h, this treatment blocked the TNF-a mediated
increased in p35 mRNA (Figure 3B). On the other hand,
Cdk5 mRNA and protein levels did not change signifi-
cantly following resveratrol treatment (data not shown).
Since the protein level of p35 is a limiting factor in
Cdk5 kinase activity [21], we analyzed whether the
resveratrol-mediated decrease in p35 expression results
in decreased Cdk5 activity. We immunoprecipitated
Cdk5 protein from the control and the resveratrol-trea-
ted cells and then assayed kinase activity by using his-
tone H1 as a substrate [18]. After 24 h of resveratrol
treatment (25 μM), Cdk5 kinase activity decreased sig-
nificantly in PC12 cells (Figure 4A and 4C) and also in
rat DRG neuronal culture (Figure 4D). We also found
that Cdk5 activity was increased by TNF-a treatment
(50 ng/ml), and that co-treatment with resveratrol (25
μM) blocked this increase (data not shown). In addition,
we found that resveratrol is able to inhibit Cdk5 activity
in mouse neuroblastoma N2a and rat neuroblastoma
B104 cell lines (data not shown). Together, these results
indicate that resveratrol treatment reduced expression of
p35, which resulted in decreased Cdk5 kinase activity.
Resveratrol treatment decreases Egr-1 mRNA and blocks
TNF-a effects in PC12 cells
Because the p35 promoter region contains several puta-
tive sequence elements, including the binding site for
transcription factor Egr-1 [19], we investigated whether
resveratrol may regulate Egr-1 expression. Egr-1 mRNA
levels were measured by real-time RT-PCR after resvera-
trol treatment, and we found that Egr-1 mRNA levels
decreased after 1 h and 2 h of resveratrol treatment (25
μM) (Figure 3C). In addition, the Egr-1 mRNA levels
increased after 1 h of TNF-a treatment (50 ng/ml), and
resveratrol blocked this increase (Figure 3D).
Resveratrol-mediated inhibition of p35 promoter activity
through MAP kinases and NF-B signaling pathways
Resveratrol is known to regulate several MAP kinase
pathways, such as ERK1/2, p38 MAPK, JNK and NF-B
pathways [22-26]. We determined the regulation of
MAP kinases and NF-B pathways by resveratrol using
Western blot analysis. We used phospho-antibodies to
determine the activation of ERK1/2, p38 MAPK, JNK
and NF-B pathways at 0-60 min (Figure 5A) and at 24
h (Figure 5B) after resveratrol treatment (25 μM) of
PC12 cells. ERK1/2 and NF-B pathways were inhibited
by resveratrol at 60 min; however, at 24 h after treat-
ment, we observed higher levels of phospho-ERK1/2 and
phospho-p65. Interestingly, p38 MAPK and JNK path-
ways remained unchanged after resveratrol treatment at
each time point they were tested.
We then examined the involvement of these pathways
in resveratrol-mediated inhibition of p35 promoter
activity, using specific inhibitors of MAP kinases and
NF-B with and without resveratrol, and measured p35
promoter activity in our stable clone C7 after 24 h of
treatment. We tested a MEK inhibitor, U0126, which is
an upstream regulator of ERK1/2 [27], as well as p38
MAPK inhibitor SB203580 [28], JNK inhibitor SP600125
[29], and an NF-B inhibitor [30]. We found that U0126
(20 μM) alone or in combination with resveratrol (25
μM) significantly decreased p35 promoter activity (Fig-
ure 6A). This indicated that the ERK1/2 pathway is
negatively regulated by resveratrol. In turn, p38 MAPK
inhibitor SB203580 (20 μM), JNK inhibitor SP600125
(20 μM) and the NF-B inhibitor (1 μM) significantly
reversed the decrease in p35 promoter activity in cells
treated with resveratrol (Figure 6B-D). This suggests
that these pathways are positively regulated by
resveratrol.
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Page 4 of 14Figure 3 Resveratrol treatment decreases p35 and Egr-1 mRNA levels and blocks the effects of TNF-a in PC12 cells. A) Real-time RT-PCR
analysis of p35 mRNA levels normalized against S29. Total RNA was obtained from PC12 cells treated with resveratrol (25 μM) for 0, 6, 15 and 24
h. After reverse transcription, we conducted real-time PCR with specific primers for p35 and S29. B) PC12 cells were treated with TNF-a (50 ng/
ml), and TNF-a (50 ng/ml) plus resveratrol (25 μM) during a 3 h period. Resveratrol blocked the increase in p35 mRNA expression induced by
TNF-a.C) Real-time RT-PCR analysis of Egr-1 mRNA levels normalized against S29. Total RNA was obtained from PC12 cells treated with
resveratrol (25 μM) for 0, 1, 2 and 4 h. After reverse transcription, we carried out real-time PCR with specific primers for Egr-1 and S29. D) PC12
cells were treated with TNF-a (50 ng/ml), and TNF-a (50 ng/ml) plus resveratrol (25 μM) during a 1 h period. Resveratrol blocked the increase in
Egr1 mRNA expression induced by TNF-a Bars are the mean and SEM of 3 independent experiments measured in triplicate. *p< 0.05, **p<0.01
(Bonferroni test after ANOVA). #p <0.05 (Bonferroni test after ANOVA), # mean value for TNF-α treatment as compared to mean value for TNF-a
plus resveratrol treatment.
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It is now known that Cdk5 plays an important role in
pain signaling and is therefore considered a potential
drug target for developing a new class of analgesics
[12-16,18]. However, very few Cdk5-specific inhibitors
have been identified so far and roscovitine remains the
lead candidate, since it has somewhat better specificity
although there were also some serious side effects
reported in early clinical trials [31,32]. Most of these
inhibitors bind to the ATP pockets of the kinases and
therefore lack the specificity needed to inhibit Cdk5
alone [33]. In order to identify additional molecules that
regulate Cdk5 with a better specificity, we developed a
cell-based assay that measures p35 promoter activity
Figure 4 Resveratrol treatment decreases p35 protein levels and Cdk5 kinase activity in PC12 cells and rat DRG neuronal cultures.A )
Representative Western blots analysis and Cdk5 kinase activity of protein from PC12 cells treated with resveratrol (Resv 25 μM) and untreated
cells (Cont) during 24 h. Resveratrol treatment decreased p35 protein levels, and Cdk5 kinase activity. The levels of Cdk5 were unchanged and a-
tubulin western blot was used as a loading control. B) Quantification of resveratrol treatment (25 μM) significantly decreased p35 protein
expression in PC12 cells. C) Quantification of resveratrol treatment (25 μM) significantly decreased Cdk5 kinase activity in PC12 cells. D)
Representative Western blots analysis and Cdk5 kinase activity of protein from rat DRG neuronal culture treated with resveratrol (Resv 25 μM)
and untreated (Cont) during 24 h. Values are shown as mean and SEM of 3 independent experiments. * p< 0.05 by using t-test.
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Page 6 of 14Figure 5 Effects of MAP kinases and the NF-B inhibitor on resveratrol-mediated inhibition of p35 promoter activity.W e s t e r nb l o t
analysis of the activation of MAP kinases and NF-B signaling pathways. Protein extract from PC12 cells untreated (Control), TNF-a treated (50
ng/ml), resveratrol treated (25 μM), and TNF-a (50 ng/ml) plus resveratrol (25 μM) treated for 0, 15, 30 and 60 min (A) and 24 h (B) were
analyzed by Western blot using phospho-ERK1/2, total ERK1/2, phospho-p38 MAPK, total p38 MAPK, phospho-JNK, total JNK, phospho-p65 and
total p65 antibodies.
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Page 7 of 14Figure 6 Effects of MAP kinases and the NF-B inhibitors on resveratrol-mediated inhibition of p35 promoter activity. A) Stable clone
C7 PC12 cells were untreated (control), treated with resveratrol (25 μM), MEK inhibitor U0126 (20 μM), and resveratrol (25 μM) plus U0126 (20
μM) during 24 h and luciferase activity was measured. Co-treatment of resveratrol plus U0126 had a further inhibitory effect over p35 promoter
activity. On the other hand, B) p38 MAP kinase inhibitor (SB203580 20 μM), C) JNK inhibitor (SP600125 20 μM) and D) NF-B inhibitor (1 μM), all
of them significantly increased p35 promoter activity in cells treated with resveratrol (25 μM). All data are presented as the mean and SEM (n =
4). a, b p< 0.05 (t-test). a mean control values compared with different treatments. b mean resveratrol values compared with resveratrol plus
corresponding inhibitor.
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that the p35 protein level is the limiting factor for Cdk5
activity in mouse brains [21], and this can be utilized to
screen for molecules that would impact Cdk5 activity
due to their effects on p35 expression. Using this cell-
based assay, we successfully identified TNF-a as a major
regulator of p35 expression and subsequently of Cdk5
kinase activity [18]. In our present work, we have
improved this cell-based assay by establishing stable
clones of PC12 cells transfected with p35-promoter-luci-
ferase construct and tested these clones for their
responses to TNF-a. We then selected one of these
clones, C7, for further experiments. Our strategy is to
use this assay to screen chemical libraries, in order to
identify novel p35 inhibitors. However, before taking on
t h ec h a l l e n g eo fs c r e e n i n gt h ec h e m i c a ll i b r a r i e s ,w e
wanted to use this cell-based assay to test the chemical
that has been implicated as playing an analgesic role,
and characterize its effects on Cdk5 activity. For that
purpose, we selected resveratrol for testing and identi-
fied it as an effective inhibitor of p35 expression and
Cdk5 activity. Resveratrol inhibited p35 expression,
which resulted in a decrease in Cdk5 activity and
blocked Cdk5 activation by TNF-a in PC12 cells and rat
DRG neuronal culture. In addition, we investigated the
mechanism underlying the inhibition of the p35 promo-
ter by resveratrol. Here we demonstrate that, through
inhibition of the ERK1/2 pathway and activation of the
NF-B pathway, resveratrol inhibits p35 expression in
PC12 cells, thereby decreasing Cdk5 kinase activity. The
inhibition of ERK1/2 by resveratrol leads to decreased
Egr-1 expression, which then results in a reduction of
p35 expression.
Resveratrol has been ascribed many therapeutic values,
including analgesic properties [1-5]. Previous studies
have demonstrated the analgesic effects of resveratrol in
rodent models of inflammation and diabetic neuropathic
pain [6,9,10,34-36]. Interestingly, anti-inflammatory
effects of resveratrol are due to its ability to regulate
levels of prostaglandins by inhibiting both COX-1 and
COX-2 [8,11,37,38]. A single injection of resveratrol
into the lateral ventricle of the brain reduced levels of
COX-1 and COX-2 with a concomitant decrease in pro-
duction of prostaglandins [8] and a decrease in the level
of pain experienced by the rodents [34]. Resveratrol is
also associated with activation of potassium channels
[39], and is known to inhibit sodium currents in rat
DRG neurons [40], although the molecular mechanism
of this regulation is not entirely understood. Gupta and
coworkers have recently demonstrated that the analgesic
effects of resveratrol are mediated via opioidergic path-
ways, whereas the analgesic effects of morphine in the
presence of resveratrol were significantly potentiated
[41]. In conjunction with these findings, our studies
have demonstrated a new molecular mechanism through
which resveratrol can regulate nociception through inhi-
bition of p35 expression and the subsequent decrease in
Cdk5 activity. This is a significant finding in light of
previous reports pointing to Cdk5 as an important key
player in the regulation of pain signaling [12,13,18].
Numerous reports have indicated that resveratrol has
different effects on MAP kinases and can inhibit the
activation of NF-B signaling in certain cells or in a tis-
sue-specific manner [22-26]. Resveratrol can either inhi-
bit or activate ERK1/2 signaling pathways depending on
the cell types or the doses used [23,24,42,43]. For exam-
ple, resveratrol at lower doses (up to 10 μM) is known
to activate the ERK1/2 pathway and, whereas, at higher
doses (50-100 μM) it can inhibit the ERK1/2 pathway in
SH-SY5Y human neuroblastoma cells [24]. Our study
shows that resveratrol (25 μM) reduced the phospho-
ERK1/2 level at 1 h, whereas it increased this level at 24
h. In addition, treatment with the MEK inhibitor
(U0126 [27]) and resveratrol produced a significant
decrease in p35 promoter activity. Moreover, resveratrol
treatment blocked TNF-a mediated activation of p35
expression and the subsequent increase in Cdk5 activity,
possibly because of decreased p35 expression due to the
down-regulation of the ERK1/2 pathway by resveratrol.
On the other hand, resveratrol also suppresses phos-
phorylation and subsequent degradation of IB, thereby
inhibiting activation of the NF-B signaling pathway.
Similarly, it also suppresses TNF-a-induced activation
of NF-B as well [37,42,44,45]. Our results are in partial
agreement with these reports, since we found that
resveratrol decreased phospho-p65 at 1 h, although it
did not block the TNF-a-mediated increase of phospho-
p65 in PC12 cells. Surprisingly, resveratrol treatment
increased the phospho-p65 level at 24 h, which is in
agreement with the reported increase of p35 promoter
activity following treatment with resveratrol and the NF-
B inhibitor, compared with resveratrol treatment alone.
These results suggest that resveratrol positively regulates
the NF-B pathway in PC12 cells, which in turn
decreases p35 expression [18]. Resveratrol regulates p38
MAPK and JNK pathways differently in different sys-
tems [25,42,46,47]. Interestingly, our study shows that
resveratrol has no effect on p38 MAPK or JNK phos-
phorylation, as determined by Western blot analysis.
However, we also observed that treatment with the p38
MAPK inhibitor (SB203580 [28]) or the JNK inhibitor
(SP600125 [29]), in the presence of resveratrol, increased
p35 promoter activity as compared with resveratrol
treatment alone. These results suggest a positive regula-
tion of the p38 MAPK and JNK pathways by resveratrol,
which in turn could decrease p35 expression.
Resveratrol treatment can increase Egr-1 expression at
different time points through the ERK1/2-dependent
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Page 9 of 14mechanism [48-50]. In contrast, our study shows that
resveratrol treatment decreased Egr-1 mRNA expression
at an early time point, and also blocked the TNF-a-
mediated increase of Egr-1 in PC12 cells. This discre-
pancy might be due to variations in the concentrations
and experimental conditions used for different studies.
Conclusions
In summary, our study demonstrates that resveratrol
regulates key components of signal transduction path-
ways that affect p35 promoter activity. Most impor-
tantly, resveratrol blocks the TNF-a-mediated increase
in p35 promoter activity, thereby reducing p35 expres-
sion and subsequent Cdk5 kinase activity (Figure 7).
This new molecular mechanism adds to the known
analgesic effects of resveratrol brought about mainly by
its regulation of COX-1 and COX-2. Finally, these find-
ings validate our cell-based assay for its use in the high
throughput screening (HTS) of chemical libraries, used
to identify potential analgesics based on their ability to
reduce Cdk5/p35 activity for the effective treatment of
pain.
Materials and methods
Materials
Resveratrol, mouse recombinant TNF-a,h i s t o n eH 1 ,
SP600125 and a-tubulin antibody were obtained from
Sigma (St. Louis, MO). SB203580, NGF and NF-B inhi-
bitor were obtained from Calbiochem (San Diego, CA).
Protein quantification reagents were obtained from Bio-
Rad Laboratories (Hercules, CA), and enhanced chemi-
luminescence reagents for Western blot analysis were
purchased from Thermo Scientific (Rockford, IL). Luci-
ferase Reporter Assay System and CellTiter 96 AQueous
One solution Cell Proliferation Assay (MTS) were
obtained from Promega (Madison, WI).
Antibodies
Antibodies to Cdk5, p35, JNK, phospho-JNK, and sec-
ondary antibodies (HRP-conjugated goat anti-mouse,
anti-rabbit antibodies) were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Antibodies to
ERK1/2, phospho-ERK1/2, p38 MAPK, phospho-p38
MAPK, NF-Bp 6 5 ,p h o s p h o - N F - B p65 and U0126
were obtained from Cell Signaling Technology (Beverly,
MA).
Cell culture
PC12 cells (derived from pheochromocytoma of rat
adrenal medulla) were obtained from American Type
Culture Collection (Rockville, MD). PC12 cells were cul-
tured in Dulbecco’s modified Eagle’sm e d i u m( D M E M ,
Invitrogen, Carlsbad, CA), supplemented with 10% fetal
bovine serum (Hyclone Laboratories, Logan, UT), peni-
cillin and streptomycin (Invitrogen, Carlsbad, CA).
Embryonic rat DRG neuronal culture
DRGs were harvested from 15-day embryonic Sprague-
Dawley rats. The tissue was dissociated in Ca
+2/Mg
+2-
free Hank’s balanced salt solution (HBSS, Invitrogen,
Carlsbad, CA) containing 0.5 U/ml Liberase Blendzyme
3 (Roche Applied Science) for 1 h at 37°C. The DRGs
were then triturated in complete growth medium
[MEM, 5% heat-inactivated horse serum (Invitrogen,
Carlsbad, CA), 50 ng/ml 2.5S murine NGF, N3 supple-
ment] with 50 μg / m lD N a s eu s i n gaf i r e - p o l i s h e dg l a s s
pipette. The suspension was enriched for neurons by
spinning on a two-layer, 30%:50% Percoll gradient (GE
Healthcare Biosciences) at 800 × g for 20 min. The Per-
coll was removed by diluting with HBSS then spinning
down the cells at 400 × g for 5 min. Cells were re-sus-
pended in complete growth medium then plated onto
poly-D-lysine/laminin coated plates. DRGs were cul-
tured 4-6 days before measurement, refreshing the med-
ium every 2 days. On the first day after plating, 10 μM
fluorodeoxyuridine was added to halt mitosis of dividing
cells in combination with 20 μM uridine to preserve
RNA synthesis. Primary DRG cultures at this stage were
treated with resveratrol (25 μM) or vehicle for 24 h.
Proteins were extracted and analyzed by Western
blotting.
Preparation of the p35 promoter-luciferase reporter
plasmid
We constructed a p35 promoter-luciferase vector by
inserting a 1,219-bp mouse p35 promoter into the
pGL4.17 (Luc2/Neo) vector from Promega (Madison,
WI). Briefly, pBluescript II SK(-) p35 promoter vector
[19] was digested with XbaIa n dXhoI, and a 1,219-bp
fragment containing the p35 promoter was cloned
between the NheI and XhoI sites of the pGL4.17 vector.
Stable transfection and reporter activity assays
p35 promoter-luciferase vector was stably transfected
into PC12 cells using Lipofectamine™ LTX and Plus™
Reagent (Invitrogen, Carlsbad, CA). Transfected cells
were subjected to drug selection by culturing them
with geneticin
® (500 μg/ml) (G418, Invitrogen, Carls-
bad, CA) for four weeks, and then several stable clones
were established. The p35 promoter-driven luciferase
activity was determined using the Luciferase
® reporter
Assay system from Promega. As reported earlier [18],
we tested several concentrations of TNF-a ( 0 ,5 ,1 0 ,
25, 50, and 100 ng/ml) during a 24 h period to
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TNF-a. Based on this testing, we selected the stable
clone C7 for further experiments. We tested luciferase
activity in stable clone C7 at different concentrations
of resveratrol (0, 5, 10, 25, and 50 μM) and different
time points (0, 1, 3, 6, 24, and 48 h). In the second set
of experiments, stable clone C7 cells were treated with
inhibitors of MAP kinases (U0126, SB203580, and
SP600125 from Sigma) or NF-B inhibitor prior to
resveratrol treatment for 24 h.
Figure 7 Proposed resveratrol-mediated regulation of p35 expression and Cdk5 activity. Resveratrol (RESV) reduces Cdk5 activity through
inhibition of p35 expression. The inhibitory effects of resveratrol on p35 expression could be brought about at several levels, inhibition of ERK1/
2 signaling pathway could affect Egr-1 expression, or activation of the p38 MAPK, JNK and NF-B signaling pathways could downregulate p35
promoter activity.
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Stable p35-promoter PC12 cells plated in 96-well plates
were serum-starved for 1 h, and treated with TNF-a (0-
100 ng/ml), resveratrol (0-100 μM), MAP kinases inhibi-
tors (U0126, 20 μM; SB203580, 20 μM; and SP600125,
20 μM) or an NF-Bi n h i b i t o r( 1μM) in serum-free
DMEM for 24 h. Cells were then incubated with CellTi-
ter 96 AQueous (MTS) solution (20 μl) from Promega
(Madison, WI). After 1 h of incubation with CellTiter
96 AQueous solution, colored MTS products in the
supernatant were transferred into 96-well microtiter
plates and absorbance at 490 nm was determined on
MicroPlate Reader Safire (Tecan, Switzerland).
RNA isolation and real-time RT-PCR
PC12 cells were grown in 6-well plates and were incu-
bated with a vehicle, TNF-a (25 ng/ml), resveratrol (10
μM) and TNF-a (50 ng/ml) plus resveratrol (25 μM) for
several time points (0, 1, 2, 3, 4, 6, 15 and 24 h) in
serum-free medium. After discarding the growth med-
ium, total RNA was isolated from the cells using TRI-
zol
® reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Following TURBO DNA-
free (Ambion, Austin, TX) digestion of the total RNA
sample, oligo (dT) primed synthesis of cDNA from 3 μg
of total RNA was made using SuperScript™III Reverse
Transcriptase (Invitrogen, Carlsbad, CA) to remove con-
taminated genomic DNA. For detection of Egr-1 and
p35 mRNA, we used real-time PCR, and the following
reaction mixture was used for these PCR samples: 1 ×
IQ™ Sybr
®Green Super Mix (Bio-Rad, Hercules, CA),
100-200 nM of each primer and 1 μlo fc D N A .c D N A
was amplified and analyzed in triplicate using Opticon
Monitor Chromo 4 (Bio-Rad, Hercules, CA). The fol-
lowing primers were used to amplify and measure the
amount of mouse mRNA by real-time RT-PCR: Egr-1 S:
5’-CCC TTC CAG GGT CTG GAG AAC CGT-3’,E g r -
1A S :5 ’-GGG GTA CTT GCG CAT GCG GCT GGG-
3’,p 3 5S :5 ’-GCC CTT CCT GGT AGA GAG CTG-3’,
p35 AS: 5’-GTG TGA AAT AGT GTG GGT CGG C-3’.
The gene expression level was normalized to S29. S29 S:
5’-GGA GTC ACC CAC GGA AGT TCG G-3’ and S29
AS: 5’-GGA AGC ACT GGC GGC ACA TG-3’.R e a l -
time PCR reactions were run in triplicate and repeated
three times.
Immunoblot Analysis
PC12 cells and rat DRG neuronal cells were lysed in T-
PER buffer (Pierce, Rockford, IL) with protease inhibitor
cocktail tablets and phosphatase inhibitor cocktail
tablets, PhosSTOP (Roche Diagnostic, Indianapolis, IN).
Protein concentration of the supernatant was deter-
mined using Bradford Protein Assay (Bio-Rad, Hercules,
CA). Proteins were separated by 4-12% SDS-PAGE gels
and transferred to nitrocellulose membranes (Invitrogen,
Carlsbad, CA). The membranes were soaked in a block-
ing buffer (5% nonfat dry milk in phosphate-buffered
saline with 0.05% Tween-20 (PBST)) for 1 h at room
temperature, and then incubated overnight at 4°C with
the appropriate primary antibody diluted in the blocking
buffer. The membranes were washed in PBST and incu-
bated for 1 h at room temperature with the secondary
antibodies diluted in blocking buffer. Immunoreactivity
was detected by SuperSignal West Pico or Dura Chemi-
luminescent Substrate (Thermo Scientific, Rockford, IL).
Membranes were stripped for 15 min at room tempera-
ture with Re-blot Plus Strong Solution (Chemicon,
Temecula, CA) and retested with a-tubulin antibodies
to normalize for protein loading. The optical densities
of the bands were quantified using an image analysis
system with Scion Image Alpha 4.0.3.2 software (Scion
Corporation, Frederick, MD).
Cdk5 Kinase Activity Assay
Cdk5 kinase activity was measured as described [14].
Briefly, 150-250 μg of protein from PC12 cells and rat
DRG neuronal culture treated with vehicle or resveratrol
(25 μM) were dissolved in T-PER buffer and immuno-
precipitated with 4 μg of anti-Cdk5 antibody C8 (Santa
Cruz, CA). Immunoprecipitated proteins (IP) were
washed 3 times in cold PBS, and 2 times in kinase buf-
fer [20 mM Tris HCl (pH 7.4), 10 mM MgCl2,1m M
EDTA, 10 μMN a Fa n d1μMN a 2VO3]. Then IP were
mixed with the kinase assay mixture [100 mM Tris HCl
(pH 7.4), 50 mM MgCl2,5m ME D T A ,5 0μMN a F ,5
μMN a 2VO3 and 5 mM DTT], using Histone H1 (1 μg/
μl) as a substrate, and the kinase activity was quantified
as described [14].
Statistical Analysis
All experiments were performed a minimum of 3 times.
Statistical evaluation was done with GraphPad Prism
software, version 4.0 (GraphPad, San Diego, CA). Signif-
icant differences between the experiments were assessed
by univariate ANOVA (more than 2 groups) or unpaired
t-tests (2 groups). ANOVA was followed by t-tests using
aB o n f e r r o n ia-correction or Dunett’s test, where a was
set to 0.05.
Abbreviations
Cdk5: cyclin-dependent kinase 5; TNF-α: tumor necrosis factor-alpha; ERK1/2:
extracellular-signal regulated kinase1/2; Egr-1: early gene response 1; TRPV1:
transient receptor potential vanilloid 1; DRG: dorsal root ganglia; CFA:
complete Freund’s adjuvant.
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